Articles tagged with: Iron
HHV-6 Infection May Be Common After Stem Cell Transplantation – Results of a retrospective Israeli study indicate that human herpesvirus 6 (HHV-6) infection is common in multiple myeloma patients after own (autologous) stem cell transplantation. HHV-6 is a family of two viruses that are present, but inactive, in most adults. If the virus becomes active in an adult, the resulting infection can cause pneumonia, suppression of blood cell production, and inflammation of the brain. The Israeli researchers found that 16 percent of patients in their study developed an HHV-6 infection after stem cell transplantation. The rate of infection was higher in patients who had received initial therapy with Velcade (bortezomib) and dexamethasone (Decadron) (20 percent) compared to those who received thalidomide (Thalomid) and dexamethasone (10 percent). The researchers recommend further studies to determine if Velcade plays a role in the development infection due to the virus. For more information, please see the study in the journal Bone Marrow Research (full text).
Iron Supplementation May Increase Velcade’s Efficacy – Results of a small Italian preclinical study show that iron supplementation may increase the efficacy of Velcade. The Italian researchers found that iron supplementation promoted protein oxidation and increased myeloma cell death. They concluded that modification of the iron status in multiple myeloma patients may be worth considering to improve the efficacy of proteasome inhibitors such as Velcade. For more information, please see the study in Haematologica (full text).
Phase 1 Clinical Trial To Study SAR650984 Plus Revlimid In Previously-Treated Myeloma Patients – The pharmaceutical company Sanofi-Aventis is starting a Phase 1 trial of SAR650984 in combination with Revlimid (lenalidomide) and dexamethasone in relapsed and refractory multiple myeloma patients. Myeloma patients must have received at least two prior therapies to be able to participate in the trial. SAR650984 belongs to the same class of drugs as elotuzumab and daratumumab, called monoclonal antibodies. Monoclonal antibodies work by identifying proteins on the surface of myeloma cells and signaling for the immune system to destroy the cancer cells. For more information, including trial locations, please see the clinical trial description.